Get the Stockscreener App
2.45
0.81%
-0.02
Mural Oncology Plc stock is traded at $2.45, with a volume of 171.33K.
It is down -0.81% in the last 24 hours and down -17.79% over the past month.
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.
See More
Previous Close:
$2.47
Open:
$2.45
24h Volume:
171.33K
Relative Volume:
0.04
Market Cap:
$44.21M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.41%
1M Performance:
-17.79%
6M Performance:
-22.96%
1Y Performance:
-24.62%
1-Day Range:
$2.44
$2.49
1-Week Range:
$2.44
$2.54
52-Week Range:
$0.95
$4.74
Mural Oncology Plc Stock (MURA) Company Profile
Name
Mural Oncology Plc
Sector
Industry
Phone
353 1 905 8020
Address
10 EARLSFORT TERRACE, DUBLIN 2
Compare MURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MURA
Mural Oncology Plc
|
2.45 | 44.21M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.87 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
509.72 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
309.70 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.15 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
247.08 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Mural Oncology Plc Stock (MURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-25-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Jun-28-24 | Initiated | Rodman & Renshaw | Buy |
| Apr-04-24 | Initiated | Morgan Stanley | Overweight |
Mural Oncology Plc Stock (MURA) Latest News
Form 8.3Mural Oncology plc - Business Wire
Two Sigma Investments LP Acquires 6,993 Shares of Mural Oncology plc (NASDAQ:MURA) - Defense World
BlackRock discloses 1.64% stake in Mural Oncology By Investing.com - Investing.com South Africa
BlackRock discloses 1.64% stake in Mural Oncology - Investing.com
BlackRock discloses 1.39% stake in Mural Oncology By Investing.com - Investing.com South Africa
BlackRock Reveals 1.58% Holding in Mural Oncology - MSN
BlackRock discloses 1.39% stake in Mural Oncology - Investing.com
BlackRock discloses stake in Mural Oncology By Investing.com - Investing.com South Africa
Kalkine : Nasdaq Index Fund and Biotechnology Sector Trends - Kalkine Media
BlackRock discloses stake in Mural Oncology - Investing.com
Jane Street Group LLC Buys New Holdings in Mural Oncology plc (NASDAQ:MURA) - Defense World
26,000 Shares in Mural Oncology plc (NASDAQ:MURA) Bought by Two Sigma Advisers LP - Defense World
Millennium Management LLC Trims Stake in Mural Oncology plc (NASDAQ:MURA) - Defense World
BlackRock reports 1.58% stake in Mural Oncology By Investing.com - Investing.com South Africa
BlackRock reports 1.58% stake in Mural Oncology - Investing.com
Mural Oncology plc (NASDAQ:MURA) Holdings Lifted by Northern Trust Corp - Defense World
Goldman Sachs adjusts positions in Mural Oncology By Investing.com - Investing.com South Africa
Goldman Sachs adjusts positions in Mural Oncology - Investing.com Australia
Mural Oncology Announces Number of Relevant Securities in Issue - The Manila Times
Goldman Sachs reports trading in Mural Oncology shares By Investing.com - Investing.com South Africa
Mural Oncology Plc Stock (MURA) Financials Data
There is no financial data for Mural Oncology Plc (MURA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Mural Oncology Plc Stock (MURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Keson-Brookes Maiken | See Remarks |
Mar 05 '25 |
Sale |
3.45 |
1,469 |
5,068 |
73,564 |
| Keson-Brookes Maiken | See Remarks |
Mar 04 '25 |
Sale |
3.36 |
1,262 |
4,240 |
75,033 |
| Loew Caroline | Chief Executive Officer |
Mar 04 '25 |
Sale |
3.36 |
4,313 |
14,492 |
305,590 |
1.86%
1.98%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):